| 摘要: |
| 目的探讨血清中期因子（S-MK）检测对非小细胞肺癌（NSCLC）辅助诊断的价值。方法选择NSCLC患者120例（观察组），同期因肺部良性肿瘤住院的患者62例（肺良性肿瘤组）及健康对照组64例，采用ELISA法测定观察组患者术前及术后（S-MK）水平，以及肺良性肿瘤组和健康对照组的S-MK水平。结果NSCLC组（术前）S-MK水平为（285.70±20.52）pg/ml，高于肺良性肿瘤组（211.88±15.69）pg/ml和健康对照组（189.06±12.92）pg/ml（t=2.402、3.257，均P＜0.01）。NSCLC组（术后1个月时）S-MK水平（218.26±10.77）pg/ml，低于术前（285.70±20.52）pg/ml，差异有统计学意义（t=3.303，P＜0.01）。结论NSCLC患者S-MK水平升高，且术后出现一定程度的下降，S-MK水平可作为一种临床肿瘤标志物，为NSCLC的诊断、疗效评价提供一定的依据。 |
| 关键词: 中期因子 非小细胞肺癌 肿瘤标记物 预后 |
| DOI： |
| 分类号: |
| 基金项目:湖州市级一般公益性科研基金项目 |
|
| Detection of serum midkine in patients with non-small cell lung cancer and its clinical significance |
|
GU Qinhua, SHEN Qibin, LI Dong, XIE Zhonghai, LI Hongwei
|
|
Huzhou Central Hospital
|
| Abstract: |
| Objective To detect serum midkine (S-MK) in patients with non-small cell lung cancer (NSCLC) and to evaluate its clinical significance. Methods The S-MK values were measured by enzyme-linked immunosorbent assay (ELISA) in 64 healthy controls, 62 patients with benign lung disease(LBD), and 120 patients with NSCLC before surgery. The S-MK values were re-examined in NSCLC patients 1 month after surgery. Results The S-MK values in patients with NSCLC were significantly higher than those in patients with LBD or healthy controls (285.70±20.52pg/ml vs. 211.88±15.69pg/ml or 189.06± 12.92, P＜0.01). S-MK significantly decreased in NSCLC patients 1month after surgery(218.26±10.77 pg/ml, P＜0.01). Conclu- sion The S-MK may be a useful serologic tumor biomarker for diagnosis and prognosis of NSCLC. |
| Key words: Midkine Non-small cell lung cancer Tumor biomarker Prognosis |
